Dasotraline Development for ADHD, Binge Eating Disorder Halted, NDAs Withdrawn
n August 2018, the Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) stating the application required additional data to further assess the efficacy and tolerability of dasotraline.